Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 334.50
Bid: 331.50
Ask: 333.00
Change: 6.00 (1.83%)
Spread: 1.50 (0.452%)
Open: 323.00
High: 344.50
Low: 323.00
Prev. Close: 328.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
10 Sep 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 08:31

Oxford Biomedica slumps as AstraZeneca vaccine trial halted

(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.

Read more
1 Sep 2020 10:27

UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares rise 1.5%, Oxford Biomedica up 2% (Adds comment on agreeme...

Read more
1 Sep 2020 10:27

CORRECTED-UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

(Corrects para 3 to say EU (not U.S.) approval for Imfinzi)* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares ...

Read more
1 Sep 2020 10:00

UPDATE 2-FTSE 100 falls to 15-week low after best August since 2014

(For a live blog on European stocks, type LIVE/ in an Eikon news window.)* FTSE 100 hit by strong pound, marks worst day since late July* Oxford Biomedica rises as AstraZeneca expands supply tie-up* British factory activity improves in August* Hom...

Read more
1 Sep 2020 08:29

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

Read more
1 Sep 2020 07:54

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

Read more
1 Sep 2020 07:54

CORRECTED-UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Corrects currency in second paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supp...

Read more
1 Sep 2020 07:54

UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Adds details on supply agreement, background)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a po...

Read more
1 Sep 2020 07:42

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

Read more
1 Sep 2020 07:35

CORRECTED-AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

(Corrects currency in first paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell t...

Read more
1 Sep 2020 07:35

AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 millio...

Read more
3 Aug 2020 08:05

Oxford Biomedica signs deal with Beam Therapeutics

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.

Read more
31 Jul 2020 11:06

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

Read more
31 Jul 2020 08:34

Oxford Biomedica signs supply deal with Axovant Gene Therapies

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.